PHASEBIO PHARMA Interest Expense (Operating)

Interest Expense (Operating) of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Interest Expense (Operating) growth rates and interactive chart.


Highlights and Quick Summary

  • Interest Expense (Operating) for the quarter ending June 29, 2021 was $254 Thousand (a -10.88% decrease compared to previous quarter)
  • Year-over-year quarterly Interest Expense (Operating) decreased by -29.83%
  • Annual Interest Expense (Operating) for 2020 was $1.45 Million (a 34.29% increase from previous year)
  • Annual Interest Expense (Operating) for 2019 was $1.08 Million (a -72.58% decrease from previous year)
  • Annual Interest Expense (Operating) for 2018 was $3.92 Million (a 44.11% increase from previous year)
  • Twelve month Interest Expense (Operating) ending June 29, 2021 was $1.23 Million (a -9.25% decrease compared to previous quarter)
  • Twelve month trailing Interest Expense (Operating) decreased by -17.32% year-over-year
Trailing Interest Expense (Operating) for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$1.23 Million $1.35 Million $1.45 Million $1.48 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Interest Expense (Operating) of PHASEBIO PHARMA

Most recent Interest Expense (Operating)of PHAS including historical data for past 10 years.

Interactive Chart of Interest Expense (Operating) of PHASEBIO PHARMA

PHASEBIO PHARMA Interest Expense (Operating) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.25 $0.29
2020 $0.33 $0.36 $0.38 $0.38 $1.45
2019 $0.37 $1.08
2018 $3.92
2017 $2.72

Business Profile of PHASEBIO PHARMA

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.